Monte Rosa Therapeutics raises $96m to develop protein-degrading molecules
ICR and Cancer Research UK spinout closes Series B financing
Read More
Tag: Monte Rosa Therapeutics
Public launch for ICR, CR UK spinout Monte Rosa
The company aims to target cancer with new drugs that take advantage of protein degradation
Read More
- Myomaker Bio unveils lab‑grown human muscle platform to transform drug testing
- Survodutide delivers 16.6% weight loss in major phase 3 obesity trial
- Kahimmune Therapeutics signs collaboration agreement with Gustave Roussy
- BioDuro and CTI Biotechnology form partnership to accelerate preclinical drug development
- Asgard Therapeutics to present new preclinical data on AT‑108 at ASGCT 2026
